A Phase 4 interventional study of peginterferon alfa-2a [Pegasys] and ribavirin [Copegus] in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 26 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-23.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 5th largest by enrollment, is one of 4 that started in 2008, is one of 48 in phase 4, and was the 62nd registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 20 · Phase 4 48
First in 2000; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,013 is above the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 129 across the 83 interventional studies. Of the 75 that completed or were terminated, 38 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 83 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
86 studies in Hepatitis C, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 84 finished, 48 (57%) have results posted.
Among the 86 studies in Hepatitis C, Chronic by Hoffmann-La Roche, this one is the 6th largest by enrollment of the 59 interventional ones that give a count, is one of 8 that started in 2008, is one of 29 in phase 4, and was the 52nd registered.
Hoffmann-La Roche’s Hepatitis C, Chronic studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 86 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multi-center study will evaluate the viral response in patients with chronic hepatitis C, genotype 1, 2, 3 \& 4 on standard anti-viral treatment with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin). Patients will receive weekly subcutaneous Pegasys plus daily oral Copegus for 24 weeks (genotype 2 \& 3) or 48 weeks (genotype 1 \& 4). Patients identified as slow responders/non-rapid virological responders will be eligible for an additional 24 weeks of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin [Copegus]
standard treatment, subcutaneously weekly
standard treatment, orally daily
Percentage of Participants With Partial Early Virological Response (pEVR) to Study Treatment
The rate of participants with pEVR to study treatment was defined as ≥ 2 log reduction in HCV-RNA level from baseline value to Week 12 of study treatment but with detectable HCV-RNA at Week 12.
Time frame: Week 12
Percentage of Participants With Complete Early Virologic Response (cEVR) to Study Treatment
The rate of participants with a cEVR to study treatment was defined as negative HCV-RNA level at Week 12 of study treatment
Time frame: Week 12
Percentage of Participants With Undetectable HCV-RNA at End of Treatment Response (ETR) at Week 24
The rate of participants with undetectable HCV-RNA at ETR at Week 24 was defined as at least a 2-log decrement in HCV-RNA from the start of treatment, but with detectable HCV-RNA at Week 12 of study treatment and undetectable HCV-RNA at Week 24 of study treatment
Time frame: Week 24
Percentage of Participants With Rapid Virologic Response (RVR) at Week 4
The rate of participants with RVR was defined as negative HCV-RNA level at Week 4 of study treatment.
Time frame: Week 4
Percentage of Participants Without a RVR (Non-RVR) at Week 4 of Standard Treatment
The rate of participants without a RVR (non-RVR) was defined as detectible HCV-RNA level at Week 4 of standard treatment.
Time frame: Week 4
Percentage of Participants With Non-RVR and Undetectable HCV-RNA at Week 24
The rate of participants with non-RVR and undetectable HCV-RNA at Week 24 was defined as detectable HCV-RNA level at Week 4 of study treatment and undetectable HCV-RNA at Week 24 of study.
Time frame: Week 24
Percentage of Participants With pEVR to Study Treatment at Week 12
The rate of participants with pEVR to study treatment was defined as ≥ 2 log reduction in HCV-RNA level from baseline value to Week 12 of study treatment but with detectable HCV-RNA at Week 12.
Time frame: Week 12
Percentge of Participants With a cEVR to Study Treatmen at Week 12 of Study Treatment
The rate of participants with a cEVR to study treatment was defined as negative HCV-RNA level at Week 12 of study treatment.
Time frame: Week 12
Percentage of Participants With Undetectable HCV-RNA at Week 24, But With Detectable HCV-RNA atWeek 12 and Undetectable HCV-RNA at Week 24
The rate of participants with undetectable HCV-RNA at ETR at Week 24 was defined as at least a 2-log decrement in HCV-RNA from the start of treatment, but with detectable HCV-RNA at Week 12 of study treatment and undetectable HCV-RNA at Week 24 of study treatment.
Time frame: Week 24
Male and female participants, 18 years of age and above with serologically proven genotype 1, 2, 3 or 4 CHC and treated with the standard combination treatment of peginterferon alfa-2a (Pegasys) and ribavirin (Copegus).
| Milestone | Pegylated Interferon Alfa 2a (Peginterferon) |
|---|---|
| Started | 1013 |
| Genotype 1 | 687 |
| Genotype 2 & 3 | 305 |
| Genotype 4 | 5 |
| Completed | 607 |
| Not completed | 406 |
| Withdrew: Other reasons | 67 |
| Withdrew: Unknown disposition | 94 |
| Withdrew: Negative hcv-rna at week 4 | 1 |
| Withdrew: Negative hcv-rna at week 12 | 4 |
| Withdrew: Decrease of less than 2-log in hcv rna | 32 |
| Withdrew: Positive hcv-rna at week 24 | 50 |
| Withdrew: Withdrawal by subject | 70 |
| Withdrew: Lost to follow-up | 88 |
The rate of participants with pEVR to study treatment was defined as ≥ 2 log reduction in HCV-RNA level from baseline value to Week 12 of study treatment but with detectable HCV-RNA at Week 12.
| Percentage of participants | Pegylated Interferon Alfa 2a (Peginterferon) |
|---|---|
| Percentage of Participants With Partial Early Virological Response (pEVR) to Study Treatment | 15.7 (12.6 to 18.1) |
The rate of participants with a cEVR to study treatment was defined as negative HCV-RNA level at Week 12 of study treatment
| Percentage of participants | Pegylated Interferon Alfa 2a (Peginterferon) |
|---|---|
| Percentage of Participants With Complete Early Virologic Response (cEVR) to Study Treatment | 50.8 (46.8 to 54.4) |
The rate of participants with undetectable HCV-RNA at ETR at Week 24 was defined as at least a 2-log decrement in HCV-RNA from the start of treatment, but with detectable HCV-RNA at Week 12 of study treatment and undetectable HCV-RNA at Week 24 of study treatment
| Percentage of participants | Pegylated Interferon Alfa 2a (Peginterferon) |
|---|---|
| Percentage of Participants With Undetectable HCV-RNA at End of Treatment Response (ETR) at Week 24 | 15.6 (12.9 to 19.2) |
The rate of participants with RVR was defined as negative HCV-RNA level at Week 4 of study treatment.
| Percentage of participants | Pegylated Interferon Alfa 2a (Peginterferon) |
|---|---|
| Percentage of Participants With Rapid Virologic Response (RVR) at Week 4 | 48.03 (42.3 to 53.6) |
The rate of participants without a RVR (non-RVR) was defined as detectible HCV-RNA level at Week 4 of standard treatment.
| Percentage of participants | Pegylated Interferon Alfa 2a (Peginterferon) |
|---|---|
| Percentage of Participants Without a RVR (Non-RVR) at Week 4 of Standard Treatment | 51.97 (46.2 to 57.6) |
The rate of participants with non-RVR and undetectable HCV-RNA at Week 24 was defined as detectable HCV-RNA level at Week 4 of study treatment and undetectable HCV-RNA at Week 24 of study.
| Percentage of participants | Pegylated Interferon Alfa 2a (Peginterferon) |
|---|---|
| Percentage of Participants With Non-RVR and Undetectable HCV-RNA at Week 24 | 6.9 (4.3 to 10.3) |
The rate of participants with pEVR to study treatment was defined as ≥ 2 log reduction in HCV-RNA level from baseline value to Week 12 of study treatment but with detectable HCV-RNA at Week 12.
No measurements were reported for this outcome.
The rate of participants with a cEVR to study treatment was defined as negative HCV-RNA level at Week 12 of study treatment.
No measurements were reported for this outcome.
The rate of participants with undetectable HCV-RNA at ETR at Week 24 was defined as at least a 2-log decrement in HCV-RNA from the start of treatment, but with detectable HCV-RNA at Week 12 of study treatment and undetectable HCV-RNA at Week 24 of study treatment.
No measurements were reported for this outcome.
Collected over Baseline to Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pegylated Interferon Alfa 2a (Peginterferon) | — | 50/1,013 (4.9%) | 131/1,013 (12.9%) |
| Event | Pegylated Interferon Alfa 2a (Peginterferon) |
|---|---|
| AnemiaBlood and lymphatic system disorders | 8/1013 |
| PancytopeniaBlood and lymphatic system disorders | 3/1013 |
| PneumoniaInfections and infestations | 3/1013 |
| Urinary tract infectionInfections and infestations | 3/1013 |
| Acute myocardial infarctionCardiac disorders | 2/1013 |
| AstheniaGeneral disorders | 2/1013 |
| AppendicitisInfections and infestations | 2/1013 |
| Haemolytic anemiaBlood and lymphatic system disorders | 1/1013 |
| Neutropenic feverBlood and lymphatic system disorders | 1/1013 |
| Atrial fibrillationCardiac disorders | 1/1013 |
| Event | Pegylated Interferon Alfa 2a (Peginterferon) |
|---|---|
| AnemiaBlood and lymphatic system disorders | 103/1013 |
| AstheniaGeneral disorders | 103/1013 |
| NeutropeniaBlood and lymphatic system disorders | 57/1013 |
All participants who enrolled in the study
| Age, Continuous(Years) | Pegylated Interferon Alfa 2a (Peginterferon) |
|---|---|
| Mean | 43.6 ± 11.3 |
| Sex/Gender, Customized(Participants) | Pegylated Interferon Alfa 2a (Peginterferon) |
|---|---|
| Female | 380 |
| Male | 632 |
| Unknown | 1 |
Ran from Sep 2008 to primary completion in Jun 2013, 56 months.
Results were first posted in Oct 2018, 5 years 4 months after primary completion.
Of 24 phase 4 interventional studies under Hepatitis C, Chronic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 48. This study's 56 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2a